281 related articles for article (PubMed ID: 25825163)
41. Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study.
Lisse I; Hasselbalch H; Junker P
APMIS; 1991 Feb; 99(2):171-8. PubMed ID: 2001283
[TBL] [Abstract][Full Text] [Related]
42. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
43. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T; Shvidel L; Aviv A; Ruchlemer R; Bairey O; Yuklea M; Herishanu Y; Braester A; Rahimi-Levene N; Vernea F; Ben-Ezra J; Bejar J; Polliack A;
Cancer; 2013 May; 119(10):1853-9. PubMed ID: 23423815
[TBL] [Abstract][Full Text] [Related]
44. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast.
Feakins RM; Wells CA; Young KA; Sheaff MT
Hum Pathol; 2000 Oct; 31(10):1214-22. PubMed ID: 11070114
[TBL] [Abstract][Full Text] [Related]
45. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
46. Properties of myelofibrosis-derived fibroblasts.
Castro-Malaspina H; Jhanwar SC
Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
[TBL] [Abstract][Full Text] [Related]
47. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Buhr T; Büsche G; Choritz H; Länger F; Kreipe H
Am J Clin Pathol; 2003 Jan; 119(1):152-8. PubMed ID: 12520711
[TBL] [Abstract][Full Text] [Related]
48. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
[TBL] [Abstract][Full Text] [Related]
49. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
[No Abstract] [Full Text] [Related]
50. Morphological and Immunophenotypical Changes of Human Bone Marrow Adipocytes in Marrow Metastasis and Myelofibrosis.
Dello Spedale Venti M; Palmisano B; Donsante S; Farinacci G; Adotti F; Coletta I; Serafini M; Corsi A; Riminucci M
Front Endocrinol (Lausanne); 2022; 13():882379. PubMed ID: 35757418
[TBL] [Abstract][Full Text] [Related]
51. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
52. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
[TBL] [Abstract][Full Text] [Related]
53. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
54. Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis.
Lehmann U; Stark H; Bartels S; Schlue J; Büsche G; Kreipe H
Clin Epigenetics; 2021 Feb; 13(1):28. PubMed ID: 33541399
[TBL] [Abstract][Full Text] [Related]
55. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
56. [Investigation and treatment of prefibrotic/early primary myelofibrosis. A case study].
Magyari F; Bedekovics J; Décsy J; Ilonczai P; Illés Á; Simon Z
Orv Hetil; 2018 Apr; 159(15):603-609. PubMed ID: 29631428
[TBL] [Abstract][Full Text] [Related]
57. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
58. Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system.
Iványi JL; Mahunka M; Papp A; Kiss A; Telek B
Haematologia (Budap); 1994; 26(2):75-86. PubMed ID: 7890265
[TBL] [Abstract][Full Text] [Related]
59. [Clinicopathologic conference. Chronic myeloproliferative disease with an increase in platelet count in the differential diagnosis of primary (essential, idiopathic) thrombocythemia (PTH)].
Zankovich R; Thiele J; Fischer R; Diehl V
Med Klin (Munich); 1986 Jan; 81(1):31-5. PubMed ID: 3785010
[No Abstract] [Full Text] [Related]
60. Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O; Muth M; Theophile K; Winter M; Hussein K; Büsche G; Kröger N; Kreipe H
Br J Haematol; 2009 Sep; 146(5):510-20. PubMed ID: 19604240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
